Rosacea
Conditions
Interventions
Experimental group :30% supramolecular salicylic acid and Intense pulsed laser
control group:Intense pulsed laser
Sponsors
Beijing Friendship Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: (1) Age 18-50 years old, gender is not limited; (2) Patients with clinical diagnosis as rosacea of erythemavascular vasodilation type (type I) and papulopustular type (type II) , with basically symmetrical lesions; (3) Willing to use the investigational drugs and treatments as required during the trial period, and avoid using any other oral/topical drugs for the treatment of rosacea during the period of receiving the investigational drugs; (4) Subjects using cosmetics must have used the same brand/type for at least 14 days prior to enrollment in the study and agree not to change the brand/type or frequency of use throughout the study; (5) Able to adhere to the use of study drugs and regular follow-up as required; (6) Have read the instructions to the subject, agree and sign the written informed consent form
Exclusion criteria
Exclusion criteria: (1) Those who are allergic to the study drug; (2) Patients with other obvious skin diseases that may affect the evaluation of efficacy or require associated treatment, such as solar dermatitis, psoriasis, seborrheic dermatitis, acne, folliculitis, eczema, etc.; (3) Severe liver and kidney diseases, blood system diseases, autoimmune diseases, chronic serious infections, diabetes, mental illness, etc.; (4) Malignant tumors or other serious diseases that may affect the evaluation of efficacy; (5) Those who are known to have severe immunocompromise, or need long-term use of corticosteroids or immunosuppressants; (6) Female subjects who are pregnant, lactating or have positive blood pregnancy during the screening period; (7) Subjects have used any of the following topical treatments before the study: (1) used within two weeks prior to the treatment: metronidazole, antibiotics (such as rythromycin, lincomycin, clindamycin, etc.), azelaic acid, benzoyl peroxide, corticosteroids, and salicylic acid; Use within four weeks prior to the treatment: topical vasoconstrictors, such as brimonidine tartrate gel and brimonidine tartrate gel or similar; Within eight weeks prior to the start of treatment: phototherapy, grinding or chemical peeling; (8) Subjects have used any of the following systemic anti-acne treatments prior to the start of the study: (1) Treatment with corticosteroids (including intramuscular injection and intralesional injection) within four weeks prior to the treatment. Stable use of intranasal inhaled or ocular corticosteroids (defined as the dose and frequency of use remaining unchanged for at least four weeks prior to initiation of treatment); (2) Use of antibiotics (doxycycline, minocycline or metronidazole/tinidazole, etc.) within four weeks before the treatment (except for continuous use for no more than 5 days); Use of isotretinoin, hydroxychloroquine, and/or adrenergic receptor inhibitors within eight weeks prior to treatment initiation (except for no more than 5 consecutive days); (9) Other reasons why the investigator believes that it is not suitable for selection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of clinical symptoms of the skin;Epidermal permeable barrier function; | — |
Secondary
| Measure | Time frame |
|---|---|
| self-symptom evaluation of patient ;Quantitative analysis of skin erythema; | — |
Countries
China
Contacts
Public ContactMeifang Wang
Beijing Friendship Hospital, Capital Medical University
Outcome results
None listed